These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 25518032)

  • 1. An analysis of tacrolimus-related complications in the first 30 days after liver transplantation.
    Nacif LS; David AI; Pinheiro RS; Diniz MA; Andraus W; Cruz RJ; D'Albuquerque LA
    Clinics (Sao Paulo); 2014 Nov; 69(11):745-9. PubMed ID: 25518032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.
    Castroagudín JF; Molina E; Romero R; Otero E; Tomé S; Varo E
    Liver Transpl; 2009 Dec; 15(12):1792-7. PubMed ID: 19938140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of modified-release tacrolimus after conversion in liver transplant patients indicates potentially favorable outcomes in selected cohorts.
    Considine A; Tredger JM; Heneghan M; Agarwal K; Samyn M; Heaton ND; O'Grady JG; Aluvihare VR
    Liver Transpl; 2015 Jan; 21(1):29-37. PubMed ID: 25312292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial.
    Nashan B; Schemmer P; Braun F; Dworak M; Wimmer P; Schlitt H
    Trials; 2015 Mar; 16():118. PubMed ID: 25873064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level.
    Nair SS; Sarasamma S; Gracious N; George J; Anish TS; Radhakrishnan R
    Exp Clin Transplant; 2015 Apr; 13 Suppl 1():197-200. PubMed ID: 25894154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 months.
    Ramirez CB; Doria C; di Francesco F; Iaria M; Kang Y; Marino IR
    J Surg Res; 2007 Apr; 138(2):198-204. PubMed ID: 17292404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation.
    Woodle ES; Bruce DS; Josephson M; Newell KA; Piper JB; Millis JM; Cronin D; Whitman G; Ruebe M; Thistlethwaite JR
    Clin Transplant; 1996 Aug; 10(4):323-32. PubMed ID: 8884103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the conversion of the immunosuppressive regimen from prograf to advagraf or to sirolimus in long-term stable liver transplant recipients: indications, safety, and outcome.
    Perrakis A; Schwarz K; Yedibela S; Croner RS; Hohenberger W; Müller V
    Transplant Proc; 2011 Dec; 43(10):3702-7. PubMed ID: 22172830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
    Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
    Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High Intrapatient Tacrolimus Variability Is Associated With Worse Outcomes in Renal Transplantation Using a Low-Dose Tacrolimus Immunosuppressive Regime.
    Whalen HR; Glen JA; Harkins V; Stevens KK; Jardine AG; Geddes CC; Clancy MJ
    Transplantation; 2017 Feb; 101(2):430-436. PubMed ID: 26950724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinically Significant Drug Interaction Between Clotrimazole and Tacrolimus in Pancreas Transplant Recipients and Associated Risk of Allograft Rejection.
    Viesselmann CW; Descourouez JL; Jorgenson MR; Radke NA; Odorico JS
    Pharmacotherapy; 2016 Mar; 36(3):335-41. PubMed ID: 26877191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tacrolimus exposure after liver transplantation in randomized controlled trials: too much for too long.
    Rodríguez-Perálvarez M; Germani G; Darius T; Lerut J; Tsochatzis E; De la Mata M; Burroughs AK
    Am J Transplant; 2013 May; 13(5):1371-2. PubMed ID: 23621166
    [No Abstract]   [Full Text] [Related]  

  • 13. Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study.
    Fischer L; Saliba F; Kaiser GM; De Carlis L; Metselaar HJ; De Simone P; Duvoux C; Nevens F; Fung JJ; Dong G; Rauer B; Junge G;
    Transplantation; 2015 Jul; 99(7):1455-62. PubMed ID: 26151607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
    DuBay D; Smith RJ; Qiu KG; Levy GA; Lilly L; Therapondos G
    Liver Transpl; 2008 May; 14(5):651-9. PubMed ID: 18433069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early tacrolimus exposure after liver transplantation: relationship with moderate/severe acute rejection and long-term outcome.
    Rodríguez-Perálvarez M; Germani G; Papastergiou V; Tsochatzis E; Thalassinos E; Luong TV; Rolando N; Dhillon AP; Patch D; O'Beirne J; Thorburn D; Burroughs AK
    J Hepatol; 2013 Feb; 58(2):262-70. PubMed ID: 23023010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of Once-Daily Extended-Release Tacrolimus Tablets Versus Twice-Daily Capsules in De Novo Liver Transplant.
    DuBay DA; Teperman L; Ueda K; Silverman A; Chapman W; Alsina AE; Tyler C; Stevens DR
    Clin Pharmacol Drug Dev; 2019 Nov; 8(8):995-1008. PubMed ID: 30667591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tacrolimus Concentration/Dose Ratio is Associated with Renal Function After Liver Transplantation.
    Thölking G; Siats L; Fortmann C; Koch R; Hüsing A; Cicinnati VR; Gerth HU; Wolters HH; Anthoni C; Pavenstädt H; Suwelack B; Schmidt HH; Kabar I
    Ann Transplant; 2016 Mar; 21():167-79. PubMed ID: 27003330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tacrolimus-related adverse effects in liver transplant recipients: its association with trough concentrations.
    Varghese J; Reddy MS; Venugopal K; Perumalla R; Narasimhan G; Arikichenin O; Shanmugam V; Shanmugam N; Srinivasan V; Jayanthi V; Rela M
    Indian J Gastroenterol; 2014 May; 33(3):219-25. PubMed ID: 24740447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits of minimizing immunosuppressive dosage according to cytochrome P450 3A5 genotype in liver transplant patients: findings from a single-center study.
    Wang L; Li N; Wang MX; Lu SC
    Genet Mol Res; 2015 Apr; 14(2):3191-9. PubMed ID: 25966085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.